Why the study?
Do Glycoprotein (GP) IIb/IIIa inhibitors improve clinical outcomes in patients with acute ischemic stroke?
Do Glycoprotein (GP) IIb/IIIa inhibitors improve clinical outcomes in patients with acute ischemic stroke?
Glycoprotein IIb/IIIa inhibitors like abciximab may have a potential role in the initial management of acute ischemic stroke and warrant further clinical trials.
No change to acute ischemic stroke management; leaves open a potential role for glycoprotein IIb/IIIa inhibitors pending randomized trials.
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.
No takes yet. Share an insight, caveat, or question.
Bogousslavsky et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: